Document:

EX-10.1

EBAY INC.

DEFERRED COMPENSATION PLAN

1

TABLE OF CONTENTS

Page

	 	 	 
	ARTICLE I. TITLE AND DEFINITIONS

	1.1

1.2

	 	Title.

Definitions.

	 	 	 
	ARTICLE II. PARTICIPATION

	ARTICLE III. CONTRIBUTIONS

	3.1

3.2

3.3

3.4

	 	Elections to Defer Compensation

Distribution Elections.

Company Contributions

FICA and Other Taxes.

	 	 	 
	ARTICLE IV. INVESTMENTS

	4.1

4.2

4.3

	 	Measurement Funds.

Investment Elections.

Compliance with Section 16 of the Exchange Act.

	 	 	 
	ARTICLE V. ACCOUNTS

	5.1

5.2

	 	Accounts.

Subaccounts.

	 	 	 
	ARTICLE VI. VESTING

	ARTICLE VII. DISTRIBUTIONS

	7.1

7.2

7.3

7.4

7.5

	 	Distribution of Accounts.

Hardship Distribution.

Effect of a Change in Control.

Inability to Locate Participant.

Prohibition on Acceleration of Distributions.

	 	 	 
	ARTICLE VIII. ADMINISTRATION

	8.1

8.2

8.3

8.4

8.5

8.6

8.7

8.8

8.9

8.10

8.11

	 	Committee.

Administrator.

Committee Action.

Powers and Duties of the Committee.

Delegation of Authority..

Construction and Interpretation.

Information.

Compensation, Expenses and Indemnity.

Quarterly Statements.

Disputes.

Compliance with Section 409A of the Code

	 	 	 
	ARTICLE IX. MISCELLANEOUS

	9.1

9.2

9.3

9.4

9.5

9.6

9.7

9.8

9.9

9.10

9.11

9.12

9.13

9.14

9.15

9.16

	 	Unsecured General Creditor.

Restriction Against Assignment.

Withholding.

Amendment, Modification, Suspension or Termination.

Designation of Beneficiary.

Governing Law.

Compliance with Code Section 162(m)

Payments on Behalf of Persons Under Incapacity.

Limitation of Rights

Exempt ERISA Plan

Notice

Errors and Misstatements

Pronouns and Plurality

Severability

Status

Headings.

2

eBay Inc., a Delaware corporation (the “Company”), and its direct and indirect
subsidiaries hereby establish and maintain this eBay Inc. Deferred Compensation Plan (the
“Plan”) which is designed to provide certain benefits for a select group of management and
highly compensated employees through deferrals of salary and incentive compensation. This Plan
shall be effective as of January 1, 2008.

The Plan is intended to comply with the requirements of Sections 409A(a)(2), (3) and (4) of
the Code and the Treasury Regulations and other guidance issued by the Secretary of the Treasury
thereunder. To the extent permitted by such Treasury Regulations or other guidance, the Plan may
be amended to conform to the requirements of Section 409A of the Code.

ARTICLE I.

TITLE AND DEFINITIONS

1.1 Title. This Plan shall be known as the eBay Inc. Deferred Compensation Plan.

1.2 Definitions.

Whenever the following words and phrases are used in this Plan, with the first letter
capitalized, they shall have the meanings specified below.

(a) “Account” or “Accounts” shall mean a Participant’s Deferral Account and/or Company
Account.

(b) “Administrator” shall mean the individuals designated by the Committee (who need not be a
member of the Committee) to handle the day-to-day Plan administration. If the Committee does not
make such a designation, the Administrator shall be the Vice-President of Human Resources
Operations of the Company, or any successor position.

(c) “Affiliate” has the meaning ascribed to such term in Rule 12b-2 promulgated under the
Exchange Act.

(d) “Base Salary” shall mean a Participant’s annual base salary, excluding bonus, incentive
and all other remuneration for services rendered to the Company, prior to reduction for any salary
contributions to a plan established pursuant to Section 125 or 423 of the Code or intended to be
qualified pursuant to Section 401(k) of the Code and prior to reduction for deferrals under this
Plan.

(e) “Beneficial Owner” has the meaning set forth in Rule 13d-3 under the Exchange Act.

(f) “Beneficiary” or “Beneficiaries” shall mean the person or persons, including a trustee,
personal representative or other fiduciary, last designated in writing by a Participant to receive
the benefits specified hereunder in the event of the Participant’s death in accordance with Section
9.5.

(g) “Board of Directors” or “Board” shall mean the Board of Directors of the Company.

(h) “Bonus” shall mean an incentive award earned by a Participant under the Company’s
short-term incentive plan.

(i) “Change in Control” shall be deemed to have occurred when any event or transaction
described in paragraph (1), (2), (3) or (4) occurs, subject to paragraph (5):

(1) Any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of
the Company representing fifty percent (50%) or more of the combined voting power of the Company’s
then outstanding securities; or

(2) The following individuals cease for any reason to constitute a majority of the number of
directors then serving: individuals who, on the Effective Date, constitute the Board and any new
director (other than a director whose initial assumption of office is in connection with an actual
or threatened election contest, including, but not limited to, a consent solicitation, relating to
the election of directors of the Company) whose appointment or election by the Board or nomination
for election by the Company’s stockholders was approved or recommended by a vote of at least
two-thirds (2/3) of the directors then still in office who either were directors on the date hereof
or whose appointment, election or nomination for election was previously so approved or
recommended; or

(3) There is consummated a merger or consolidation of the Company or any direct or indirect
subsidiary of the Company with any other corporation, other than (A) a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior to such
merger or consolidation continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity or any parent thereof), in combination
with the ownership of any trustee or other fiduciary holding securities under an employee benefit
plan of the Company or any subsidiary of the Company, at least a majority of the combined voting
power of the securities of the Company or such surviving entity or any parent thereof outstanding
immediately after such merger or consolidation, or (B) a merger or consolidation effected to
implement a recapitalization of the Company (or similar transaction) in which no Person is or
becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including
in the securities beneficially owned by such Person any securities acquired directly from the
Company or its affiliates other than in connection with the acquisition by the Company or its
affiliates of a business) representing fifty percent (50%) or more of the combined voting power of
the Company’s then outstanding securities; or

(4) The stockholders of the Company approve a plan of complete liquidation or dissolution of
the Company or there is consummated an agreement for the sale or disposition by the Company of all
or substantially all of the Company’s assets, other than a sale or disposition by the Company of
all or substantially all of the Company’s assets to an entity, at least a majority of the combined
voting power of the voting securities of which are owned by stockholders of the Company in
substantially the same proportions as their ownership of the Company immediately prior to such
sale.

(5) An event or transaction described in paragraph (1), (2), (3), or (4) shall be a “Change in
Control” only if such event or transaction is a “change in the ownership or effective control of
the corporation, or in the ownership of a substantial portion of the assets of the corporation,”
within the meaning of Section 409A(a)(2)(A)(v) of the Code, to the extent provided by the Secretary
of the Treasury.

(j) “Code” shall mean the Internal Revenue Code of 1986, as amended.

(k) “Committee” shall mean the Compensation Committee of the Board of Directors.

(l) “Company” shall mean eBay Inc. and any successor corporations. Company shall also include
each corporation which is a member of a controlled group of corporations (within the meaning of
Section 414(b) of the Code) of which eBay Inc. is a component member.

(m) “Company Account” shall mean the bookkeeping account maintained by the Company for each
Participant that is credited with an amount equal to the Company Contribution, if any, debited by
amounts equal to all distributions to and withdrawals made by the Participant and/or his
Beneficiary and adjusted for investment earnings and losses pursuant to Article V.

(n) “Company Contributions” shall mean any discretionary employer contribution, if any, made
to the Plan on behalf of Eligible Individuals.

(o) “Compensation” shall mean Base Salary and Bonus, and at the Committee’s discretion,
Restricted Stock Units that the Participant who is an employee is entitled to receive for services
rendered to the Company.

(p) “Deferral Account” shall mean the bookkeeping account maintained by the Company for each
Participant that is credited with amounts equal to the portion of the Participant’s Compensation
that he elects to defer pursuant to Section 3.1, debited by amounts equal to all distributions to
and withdrawals made by the Participant and/or his Beneficiary and adjusted for investment earnings
and losses pursuant to Article V. The Deferral Account may be further subdivided into subaccounts
as determined by the Committee.

(q) “Deferral Election Form” shall mean the form designated by the Committee for purposes of
making deferrals under Section 3.1.

(r) “Disability” or “Disabled” means, with respect to a Participant, that the Participant:

(1) is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or can be
expected to last for a continuous period of not less than twelve (12) months, or

(2) is, by reason of any medically determinable physical or mental impairment which can be
expected to result in death or can be expected to last for a continuous period of not less than
twelve (12) months, receiving income replacement benefits for a period of not less than three
months under an accident or health plan covering employees of such Participant’s Employer,

as determined in accordance with Section 409A(a)(2)(C) of the Code and the Treasury Regulations
thereunder.

(s) “Distributable Amount” of a Participant’s subaccounts with respect to a Plan Year shall
mean the sum of the vested balance of the subaccount in a Participant’s Deferral Account and
Company Account with respect to such Plan Year.

(t) “Effective Date” shall mean January 1, 2008.

(u) “Election Period” with respect to a Plan Year shall mean the period designated by the
Committee; provided, however, that such period shall be no less than ten business days. The
Election Period with respect to a Plan Year shall end not later than the last day of the prior Plan
Year; provided, however, that, in the case of an Eligible Individual who first becomes eligible to
participate in the Plan during a Plan Year, the Election Period may be the thirty (30) day period
commencing on the date such Eligible Individual first becomes eligible to participate in accordance
with Section 409A(a)(4)(B)(ii) of the Code and the Treasury Regulations thereunder; and provided,
further, in the case of an Eligible Individual’s election to defer a Bonus (or portion thereof) for
a Plan Year that is performance-based compensation based on services over a period of at least
twelve (12) months, within the meaning of Section 409A(a)(4)(B)(iii) of the Code and the Treasury
Regulations thereunder, the Election Period may be a period designated by the Committee during such
Plan Year that satisfies the requirements of Section 409A(a)(4)(B)(iii) of the Code and the
Treasury Regulations thereunder.

(v) “Eligible Individual” shall mean those Executives selected by the Committee. The
Committee may, in its sole discretion, select such other individuals to participate in the Plan who
do not otherwise meet the foregoing designation.

(w) “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended.

(x) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the
applicable rules and regulations thereunder.

(y) “Executive” shall mean an executive of the Company who is on the U.S. payroll and who
holds a position as Vice President or who holds a position with a more senior grade level than Vice
President, or is otherwise designated by the Committee.

(z) “401(k) Plan” shall mean the eBay Inc. 401(k) Savings Plan maintained by the Company under
Code Section 401(k), as in effect from time to time or as applicable for any Participant, a plan
maintained by a direct or indirect subsidiary of the Company under Code Section 401(k).

(aa) “Measurement Fund” shall mean one or more of the investment funds selected by the
Committee pursuant to Section 4.1.

(bb) “Participant” shall mean any Eligible Individual who becomes a Participant in accordance
with Article II and who has not received a complete distribution of the amounts credited to his
Accounts.

(cc) “Payroll Date” shall mean, with respect to any Participant, the date on which he would
otherwise be paid Compensation.

(dd) “Payment Date” shall mean the time as soon as practicable after one of the following
dates as designated by the Participant in his distribution form election with respect to a Plan
Year:

(1) the first business day of the seventh calendar month following the date of the
Participant’s Separation from Service or Disability, or

(2) the earlier of: (i) the first business day of June of a calendar year specified by the
Participant that is no earlier than the year after the year in which the Compensation would have
been paid but for the Participant’s election to defer such Compensation, or (ii) the first business
day of the seventh calendar month following the date of the Participant’s Separation from Service
or Disability.

“Payment Date” shall also mean the Scheduled In-Service Withdrawal Date elected in accordance
with the provisions of Section 7.1(b).

(ee) “Person” means any person, entity or “group” within the meaning of Section 13(d)(3) or
Section 14(d)(2) of the Exchange Act, except that such term shall not include (1) the Company or
any of its Affiliates, (2) a trustee or other fiduciary holding securities under an employee
benefit plan of the Company or any of its Affiliates, (3) an underwriter temporarily holding
securities pursuant to an offering of such securities, (4) a corporation owned, directly or
indirectly, by the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company, or (5) a person or group as used in Rule 13d-1(b) under the
Exchange Act.

(ff) “Plan” shall mean the eBay Inc. Deferred Compensation Plan set forth herein, as amended
from time to time.

(gg) “Plan Year” shall mean the twelve (12) consecutive month period beginning on each January
1 and ending on each December 31.

(hh) “Restricted Stock Units” shall mean restricted stock units granted to Executives under
the eBay Inc. 2008 Incentive Award Plan, eBay Inc. 1999 Global Equity Incentive Plan and eBay Inc.
1998 Equity Incentive Plan, or any other equity compensation plans approved by the Company’s
Stockholders.

(ii) “Rule 16b-3” shall mean that certain Rule 16b-3 under the Exchange Act, as such Rule may
be amended from time to time.

(jj) “Scheduled In-Service Withdrawal Date” shall mean the earlier of: (i) the first business
day of June of a calendar year specified by the Participant that is no earlier than the year after
the year in which the Compensation would have been paid but for the Participant’s election to defer
such Compensation, or (ii) the first business day of the seventh calendar month following the date
of the Participant’s Separation from Service or Disability.

(kk) “Separation from Service” shall mean with respect to a Participant, such Participant’s
Termination, if such Termination is a “separation from service,” within the meaning of Section
409A(a)(2)(A)(i) of the Code, as determined by the Secretary of the Treasury (or such Participant’s
other “separation from service,” as so defined).

(ll) “Subaccount” or “Subaccounts” shall mean the subaccount or subaccounts maintained with
respect to a Participant’s Deferral Account or Company Account.

(mm) “Termination” shall mean for any Participant who is an employee, ceasing to be an
employee of the Company for reasons other than death or Disability. If a Participant is both an
employee of the Company and a member of the Board of Directors, he shall not have a Termination
until he resigns from both positions.

(nn) “Valuation Date”, with respect to the Measurement Funds that are available under the
401(k) Plan, shall have the same meaning as under the 401(k) Plan. For purposes of other
Measurement Funds, “Valuation Date” shall be as determined by the Committee.

ARTICLE II.

PARTICIPATION

(a) An Eligible Individual shall become a Participant in the Plan by (1) electing to make
deferrals in accordance with Section 3.1 or receiving a Company Contribution and (2) filing with
the Company such other forms as the Committee may reasonably require for participation hereunder.

(b) An Eligible Individual who completes the requirements of the preceding subsection of this
Article II shall commence participation in this Plan as of the first day of the Plan Year with
respect to which Compensation is elected to be deferred.

ARTICLE III.

CONTRIBUTIONS

3.1 Elections to Defer Compensation

(a) General Rule. Each Eligible Individual may defer Compensation for a Plan Year by filing
with the Administrator a Deferral Election Form for such Plan Year that conforms to the
requirements of this Section 3.1, no later than the last day of the applicable Election Period for
such Plan Year. The Committee may permit an Eligible Individual who first becomes eligible to
participate in the Plan during a Plan Year to have his first Election Period during such Plan Year.
An election to defer Compensation for a Plan Year must be filed during the Election Period prior
to the effective date of such election and shall be effective only for Compensation that
constitutes compensation for services performed during periods during the Plan Year beginning after
the effective date of such election. Notwithstanding the previous sentence, if an Eligible
Individual’s Bonus (or portion thereof) is a performance-based compensation based on services
performed over a period of at least twelve (12) months, within the meaning of Section
409A(a)(4)(B)(iii) and the Treasury Regulations thereunder, the Committee may permit such Eligible
Individual to file an election to defer such Bonus (or such portion thereof), or change such
Eligible Individual’s prior election to defer such Bonus (or such portion thereof), no later than
six months before the end of the period over which such services are to be performed, under the
terms and conditions specified by the Committee, in accordance with Section 409A(a)(4)(B)(iii) of
the Code and the Treasury Regulations thereunder. A Participant shall make a separate election to
defer Compensation for each Plan Year.

(b) Special Rules. Notwithstanding the above, the following restrictions apply to deferrals
of Restricted Stock Units.

(1) Restricted Stock Units. A Participant may elect to defer Restricted Stock Units (or a
portion thereof), to the extent permitted by the Committee. In order to defer Restricted Stock
Units (or a portion thereof), an eligible Participant must file the appropriate Deferral Election
Form no later than the election date required under Section 409A of the Code and the Treasury
Regulations thereunder. A Participant’s election to defer Restricted Stock Units shall be
effective only for the Restricted Stock Units (or a portion thereof) that constitute compensation
for services performed during periods during the Plan Year (or a subsequent Plan Year) after the
effective date of the Participant’s deferral election, or as otherwise permitted under Section 409A
of the Code and the Treasury Regulations thereunder.

(2) Limitation on Deferrals. A Participant may elect to defer Restricted Stock Units or any
portion thereof, only to the extent such deferral satisfies the requirements of Section 409A of the
Code and the Treasury Regulations thereunder.

(c) Deferral Amounts.

(1) The amount of Compensation which a Participant may elect to defer for a Plan Year is such
Compensation earned on or after the time at which the Participant elects to defer each Plan Year in
accordance with Section 3.1(a), and which is earned during such Plan Year. The applicable
limitations for any Participant shall be determined by the Committee, determined as of the first
day of the Election Period for such Plan Year.

(2) Each Participant shall be permitted to defer, in any whole percentage: (A) from 5% to 50%
of Base Salary, (B) from 5% to 100% of his Bonus and (C) from 5% to 100% of his Restricted Stock
Units, subject to Section 3.1(b), rounded down to the nearest whole share.

(c) Notwithstanding the limitations established above, the total amount deferred by a
Participant shall be limited in any calendar year, if necessary, to satisfy the Participant’s
income and employment tax withholding obligations (including Social Security, unemployment and
Medicare), and the Participant’s employee benefit plan contribution requirements, determined on the
first day of the Election Period for such Plan Year, as determined by the Committee.

(d) Duration of Deferral Election.

(1) A Participant shall not modify or suspend his election to defer Compensation during a Plan
Year.

(2) A Participant must file a new deferral election for each subsequent Plan Year. In the
event a Participant fails to file a timely deferral election for the next Plan Year, he shall be
deemed to have elected not to defer any Compensation for such Plan Year.

(e) Elections. Subject to the limitations of subsection (b), any Eligible Individual who does
not elect to defer Compensation during his Election Period for a Plan Year may subsequently become
a Participant.

3.2 Distribution Elections.

(a) General Rule. Each Participant shall make a separate distribution election with respect
to each Plan Year for which such Participant elects to defer Compensation in accordance with
Section 3.1. A Participant’s distribution election with respect to a Plan Year shall apply to:
(1) the subaccount in his Deferral Account to which shall be credited the amount equal to the
portion of his Compensation earned during such Plan Year that he elects to defer pursuant to
Section 3.1; and (2) the subaccount in his Company Account to which shall be credited the amount
equal to the Company Contribution for such Plan Year, if any. A Participant’s distribution
election with respect to a Plan Year shall elect the Payment Date and the form of distribution of
his Distributable Amount with respect to such Plan Year for purposes of distributions under
subsection 7.1(a) in the event of such Participant’s Separation from Service or Disability. Such
Payment Date and distribution form elections shall be made on such Participant’s Deferral Election
Form during the Election Period for which such Participant elects to defer Compensation under
Section 3.1 for such Plan Year, and such Payment Date and distribution form elections with respect
to such Plan Year shall be irrevocable, except as provided in subsection (b). A Participant may
elect any Payment Date described in Section 1.2(dd), and may elect distribution in the normal form,
as described in paragraph 7.1(a)(1), or an optional form described in subparagraphs 7.1(a)(2)(A),
(B) or (C). In the event a Participant fails to elect a Payment Date for his Distributable Amount
with respect to a Plan Year, his Payment Date for his Distributable Amount with respect to such
Plan Year shall be the date described in Section 1.2(dd)(1). In the event a Participant fails to
make a distribution form election for his Distributable Amount with respect to a Plan Year, his
Distributable Amount with respect to such Plan Year shall be distributed in the normal form, as
described in paragraph 7.1(a)(1) in the event of his Separation from Service or Disability, except
as provided in subsection (b). Except as provided in subsection (b), a Participant’s distribution
for his Distributable Amount with respect to a Plan Year shall be made or commence as soon as
administratively practicable after such Participant’s Payment Date.

(b) Changes to Distribution Form Election. Subject to subsection (e), a Participant may
change his distribution form election for his Distributable Amount with respect to a Plan Year in
accordance with this subsection (b) as follows:

(1) Change from Lump Sum. If such Participant elected to receive the distribution of his
Distributable Amount with respect to a Plan Year in the event of his Separation from Service or
Disability in the normal form, as described in paragraph 7.1(a)(1) ( i.e., a lump sum), such
Participant may change such distribution form election by making a new distribution form election
for his Distributable Amount with respect to such Plan Year providing for distribution in one of
the following forms, with such distribution made or commencing on the fifth anniversary of his
initially elected Payment Date:

(A) a lump sum, or

(B) annual installments (calculated as set forth at Section 7.1(a)(6)) over a period of from
two (2) up to fifteen (15) years.

(2) Change from Installments. If such Participant elected to receive the distribution of his
Distributable Amount with respect to a Plan Year in the event of his Separation from Service or
Disability in an optional form, as provided in subparagraph 7.1(a)(2) (i.e., annual installments
over a period of years), such Participant may change such distribution form election by making a
new distribution form election for his Distributable Amount with respect to such Plan Year
providing for distribution in one of the following forms, with such distribution commencing on the
fifth anniversary of his initially elected Payment Date:

(i) a lump sum, provided that no installments have commenced with respect to such Plan Year,

(ii) annual installments (calculated as set forth at Section 7.1(a)(6)) over the period of
years specified in such Participant’s initial distribution form election, provided that no
installments have commenced with respect to such Plan Year, or

(iii) annual installments (calculated as set forth at Section 7.1(a)(6)) over a period of from
two (2) up to fifteen (15) years, provided that such period exceeds the period of years specified
in such Participant’s initial distribution form election, and provided, further, that no
installments have commenced with respect to such Plan Year.

(3) A Participant may make only one change to his distribution form election with respect to a
Plan Year under this subsection (b).

(c) Election of Scheduled In-Service Withdrawal Date. A Participant may elect a Scheduled
In-Service Withdrawal Date with respect to his deferrals of Compensation (including any investment
earnings on such amounts) plus any Company Contributions to the extent vested, if any, (the
“Withdrawal Amount”) with respect to a Plan Year. Such election of a Scheduled In-Service
Withdrawal Date for such Participant’s Withdrawal Amount with respect to a Plan Year shall be made
by such Participant during the Election Period for which such Participant elects to defer
Compensation under Section 3.1 for such Plan Year, and such election of a Scheduled In-Service
Withdrawal Date shall be irrevocable, except as provided in subsection (d). A Participant may make
separate Scheduled In-Service Withdrawal Date elections for his deferrals of Compensation
(including any investment earnings on such amounts) with respect to different Plan Years. A
Participant’s Withdrawal Amount with respect to a Plan Year shall be credited to subaccounts under
such Participant’s Accounts for such Plan Year. A Participant shall not be required to elect a
Scheduled In-Service Withdrawal Date with respect to his deferrals of Compensation for a Plan Year
and, if a Participant fails to make an election of a Scheduled In-Service Withdrawal Date for a
Plan Year, no Scheduled In-Service Withdrawal Date shall apply with respect to his deferrals of
Compensation for such Plan Year.

(d) Change of Scheduled In-Service Withdrawal Date. Subject to subsection (e), if a
Participant elected a Scheduled In-Service Withdrawal Date with respect to his deferrals of
Compensation (including any investment earnings on such amounts) with respect to a Plan Year, such
Participant may change such Scheduled In-Service Withdrawal Date for the Withdrawal Amount with
respect to such Plan Year by electing a new Scheduled In-Service Withdrawal Date for the Withdrawal
Amount with respect to such Plan Year that is not less than five years later than the Scheduled
In-Service Withdrawal Date previously elected by such Participant for such Plan Year. A
Participant who has not elected a Scheduled In-Service Withdrawal Date for his deferrals of
Compensation (including any investment earnings on such amounts) for a Plan Year may not
subsequently elect a Scheduled In-Service Withdrawal Date for his deferrals of Compensation
(including any investment earnings on such amounts) for such Plan Year. A Participant may make
only one change to the Scheduled In-Service Withdrawal Date with respect to each Plan Year under
this subsection (d).

(e) Limitation on Distribution Changes. A Participant’s election to change his distribution
form election with respect to a Plan Year under subsection (b), or change of a Scheduled In-Service
Withdrawal Date with respect to a Plan Year under subsection (d), shall be subject to the following
limitations:

(1) The Participant’s election to change his distribution election form with respect to a Plan
Year, or change his Scheduled In-Service Withdrawal Date with respect to a Plan Year, shall not
take effect until at least twelve (12) months after his election to change the distribution form
election, or Scheduled In-Service Withdrawal Date, is made. If the distribution of such
Participant’s Distributable Amount with respect to a Plan Year (in the case of a change in his
distribution election form), or the distribution of the Withdrawal Amount with respect to such Plan
Year (in the case of a change in his Scheduled In-Service Withdrawal Date), is made or commenced
before the election to change his distribution form election or Scheduled In-Service Withdrawal
Date, as the case may be, becomes effective, the election to change his distribution form election
or Scheduled In-Service Withdrawal Date shall not thereafter become effective, and distributions
shall be made in accordance with the distribution form election, and Scheduled In-Service
Withdrawal Date (if any), as applicable, in effect prior to the Participant’s election to change.

(2) The Participant’s election to change his distribution election form with respect to a Plan
Year, or change his Scheduled In-Service Withdrawal Date with respect to a Plan Year, shall provide
that each payment with respect to such new distribution form election, or new Scheduled In-Service
Withdrawal Date, shall be deferred for a period of not less than five years from the date such
payment would otherwise have been made.

(3) The Participant’s election to change his Scheduled In-Service Withdrawal Date with respect
to a Plan Year shall not be made less than twelve (12) months prior to the date of the first
scheduled payment under the Participant’s initial election of the Scheduled In-Service Withdrawal
Date with respect to such Plan Year.

The limitations under this subsection (e) shall be applied in accordance with Section 409A(a)(4)(C)
of the Code and the Treasury Regulations thereunder.

3.3 Company Contributions

(a) For any Plan Year, the Company may, but is under no obligation to, make contributions on
behalf of a Participant in addition to the Participant’s elective deferrals. Such contributions
may be in any amount or form (for example, matching or profit sharing contributions) and subject to
any conditions or terms as the Company, in its sole discretion, deems appropriate.

(b) The Company Contribution for a Plan Year shall be credited to a Participant’s Company
Account in the manner determined by the Committee.

3.4 FICA and Other Taxes.

(a) Annual Deferral Amounts. For each Plan Year in which a Participant who is an employee
makes a deferral under Section 3.1, the Company shall withhold from that portion of the
Participant’s Compensation that is not being deferred, in a manner determined by the Company, the
Participant’s share of FICA and other employment taxes on such amount. If necessary, the Committee
may reduce the Participant’s deferrals under Section 3.1 or make deductions from his Deferral
Account in order to comply with this Section, to the extent permitted under Section 409A of the
Code and the Treasury Regulations thereunder.

(b) Company Amounts. For each Plan Year in which a Participant is credited with a
contribution to his Company Account under Section 3.3, the Company shall withhold from the
Participant’s Compensation that is not deferred, in a manner determined by the Company, the
Participant’s share of FICA and other employment taxes. If necessary, the Committee may reduce the
Participant’s Company Account in order to comply with this Section, to the extent permitted under
Section 409A of the Code and the Treasury Regulations thereunder.

ARTICLE IV.

INVESTMENTS

4.1 Measurement Funds.

(a) In the manner designated by the Committee, Participants may elect one or more Measurement
Funds to be used to determine the additional amounts to be credited to their Accounts. Although
the Participant may designate the Measurement Funds, the Committee shall not be bound by such
designation. The Committee shall select from time to time, in its sole discretion, the Measurement
Funds to be available under the Plan.

(b) No Actual Investment. Notwithstanding any other provision of this Plan that may be
interpreted to the contrary, the Measurement Funds are to be used for measurement purposes only,
and a Participant’s election of any such Measurement Fund, the allocation to his Accounts thereto,
the calculation of additional amounts and the crediting or debiting of such amounts to a
Participant’s Accounts shall not be considered or construed in any manner as an actual investment
of his Accounts in any such Measurement Fund. In the event that the Company, in its own
discretion, decides to invest funds in any or all of the Measurement Funds, no Participant shall
have any rights in or to such investments themselves. Without limiting the foregoing, a
Participant’s Accounts shall at all times be a bookkeeping entry only and shall not represent any
investment made on his behalf by the Company. The Participant shall at all times remain an
unsecured creditor of the Company.

4.2 Investment Elections.

(a) Deferral Accounts and Company Accounts. Except as provided in Section 4.3, Participants
may designate how their Deferral Accounts and Company Accounts, if any, shall be deemed to be
invested under the Plan.

(1) Such Participants may make separate investment elections for (i) their future deferrals of
Compensation, (ii) future Company Contributions and (iii) the existing balances of their Accounts.

(2) Such Participants may make and change their investment elections by choosing from the
Measurement Funds designated by the Committee in accordance with the procedures established by the
Committee.

(3) Except as otherwise designated by the Committee, the available Measurement Funds under
this Section 4.2(a)(1) shall generally be the investment funds under the 401(k) Plan (excluding any
brokerage account option).

(4) If a Participant fails to elect a Measurement Fund under this Section, he shall be deemed
to have elected the default Measurement Fund (as designated by the Committee) for all of his
Accounts.

(b) Continuing Investment Elections. Participants who have had a Termination but not yet
commenced distributions under Article VII or Participants or Beneficiaries who are receiving
installment payments may continue to make investment elections pursuant to subsection (a) and (b)
above, as applicable, except as otherwise determined by the Committee.

(c) Certain Deferral Subaccounts. A Participant may not direct the investment of the
Restricted Stock Unit subaccounts of the Deferral Accounts.

4.3 Compliance with Section 16 of the Exchange Act.

(a) Any Participant or Beneficiary who is subject to Section 16 of the Exchange Act shall have
his Measurement Fund elections under the Plan subject to the requirements of the Exchange Act, as
interpreted by the Committee.

(b) Notwithstanding any other provision of the Plan or any rule, instruction, election form or
other form, the Plan and any such rule, instruction or form shall be subject to any additional
conditions or limitations set forth in any applicable exemptive rule under Section 16 of the
Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of
such exemptive rule. To the extent permitted by applicable law, such Plan provision, rule,
instruction or form shall be deemed amended to the extent necessary to conform to such applicable
exemptive rule.

ARTICLE V.

ACCOUNTS

5.1 Accounts.

(a) The Committee shall establish and maintain a Deferral Account, and a Company Account for
each Participant under the Plan. Each Participant’s Accounts shall be divided into separate
subaccounts in accordance with Section 5.2. Each such subaccount shall be further divided into
separate investment fund subaccounts, each of which corresponds to a Measurement Fund elected by
the Participant pursuant to Section 4.2. In addition, participants’ Deferral Accounts may be
further divided into subaccounts consisting of deferred Restricted Stock Units.

(b) The performance of each elected Measurement Fund (either positive or negative) shall be
determined by the Committee, in its reasonable discretion, based on the performance of the
Measurement Funds themselves. A Participant’s Accounts shall be credited or debited on each
Valuation Date based on the performance of each Measurement Fund selected by the Participant, as
determined by the Committee in its sole discretion, as though (i) a Participant’s Accounts were
invested in the Measurement Fund(s) selected by the Participant, in the percentages applicable to
such period, as of the close of business on the first business day of such period, at the closing
price on such date; (ii) the portion of the Participant’s Compensation that was actually deferred
pursuant to Section 3.1 during any period were invested in the Measurement Fund(s) selected by the
Participant, in the percentages applicable to such period, no later than the close of business on
the first business day after the day on which such amounts are actually deferred from the
Participant’s Compensation, at the closing price on such date; and (iii) any withdrawal or
distribution made to a Participant that decreases such Participant’s Accounts ceased being invested
in the Measurement Fund(s), in the percentages applicable to such period, no earlier than one
business day prior to the distribution, at the closing price on such date. The Participant’s
Company Contributions, if any, shall be credited to his Company Account for purposes of this
Section, in the manner determined by the Committee.

	5.2	 	Subaccounts.

(a) The Committee shall establish and maintain, with respect to a Participant’s Deferral
Account, a subaccount with respect to each Plan Year, to which shall be credited the amount equal
to the portion of the Participant’s Compensation earned during such Plan Year that he elects to
defer pursuant to Section 3.1, debited by amounts equal to distributions to and withdrawals made by
the Participant and/or his Beneficiary and adjusted for investment earnings and losses pursuant to
Article V.

(b) The Committee shall establish and maintain, with respect to a Participant’s Company
Account, a subaccount with respect to each Plan Year, to which shall be credited the amount equal
to the Company Contributions, if any, made pursuant to Section 3.3 on behalf of such Participant
during such Plan Year, debited by amounts equal to distributions to and withdrawals made by the
Participant and/or his Beneficiary and adjusted for investment earnings and losses pursuant to
Article V.

ARTICLE VI.

VESTING

Each Participant shall be 100% vested in his Deferral Account at all times, provided, however,
that any Restricted Stock Units a Participant elects to defer shall remain subject to the
conditions for vesting specified in any applicable award notice or agreement. The Company will set
conditions for the vesting of any Company Contributions on or before the date they are contributed
to the Plan.

ARTICLE VII.

DISTRIBUTIONS

7.1 Distribution of Accounts.

(a) Distribution of Accounts.

(1) Normal Form. Except as provided in paragraph (2), paragraph (3) or Section 7.3, a
Participant’s Distributable Amount with respect to each Plan Year shall be paid to the Participant
in a single lump sum in cash on the Participant’s Payment Date.

(2) Optional Forms. Instead of receiving his Distributable Amount with respect to each Plan
Year as described at Section 7.1(a)(1), the Participant may elect in accordance with Section 3.2 an
optional form of payment (on the form provided by Company) at the time of his deferral election for
such Plan Year to receive his Distributable Amount in equal annual installments in cash (calculated
as set forth in Section 7.1(a)(6)) over a period of from two (2) up to fifteen (15) years beginning
on the Participant’s Payment Date. The payment of such Participant’s Distributable Amount with
respect each Plan Year shall be made or commence on such Participant’s Payment Date.

(3) Distribution Election Changes. In the event that a Participant changes his distribution
form election with respect to a Plan Year in accordance with Section 3.2(b), and such new
distribution form election becomes effective upon the Separation from Service or Disability of such
Participant, the Distributable Amount with respect to such Plan Year shall be paid to the
Participant in accordance with such new distribution form election.

(4) Small Accounts. Notwithstanding any provision to the contrary, in the event the total of
a Participant’s Distributable Amounts with respect to all Plan Years is equal to or less than
$50,000 on the Participant’s Payment Date, such Distributable Amounts shall be distributed to the
Participant (or his Beneficiary, as applicable) in a lump sum.

(5) Investment Adjustments. The Participant’s Accounts shall continue to be adjusted for
investment earnings and losses pursuant to Section 4.2 and Section 4.3 of the Plan until all
amounts credited to his Accounts under the Plan have been distributed.

(6) Calculating Installments. All installment payments made under the Plan shall be
determined in accordance with the annual fractional payment method, calculated as follows: the
balance of subaccounts in the Participant’s Accounts with respect to a Plan Year shall be
calculated as of the close of business on the last business day of the year. The annual
installment shall be calculated by multiplying this balance by a fraction, the numerator of which
is one, and the denominator of which is the remaining number of annual payments due the
Participant. By way of example, if the Participant elects 10 year installments for the
distribution of the subaccounts in his Accounts with respect to a Plan Year, the first payment
shall be 1/10 of the balance of such subaccounts in his Accounts calculated as described in this
definition. The following year, the payment shall be 1/9 of such subaccounts in the balance of the
Participant’s Accounts, calculated as described in this definition. Each annual installment shall
be paid on or as soon as practicable after the last business day of the applicable year.

(b) Distribution on a Scheduled In-Service Withdrawal Date.

(1) In the case of a Participant who has elected a Scheduled In-Service Withdrawal Date for a
distribution to be made while still in the employ of the Company, such Participant shall receive
his Withdrawal Amount as shall have been elected by the Participant to be subject to the Scheduled
In-Service Withdrawal Date. A Participant’s Scheduled In-Service Withdrawal Date with respect to
amounts of Compensation deferred in a given Plan Year must be at least one year from the last day
of the Plan Year for which such deferrals are made.

(2) The Participant may elect, in accordance with Section 3.2, to have the Withdrawal Amount
paid in a lump sum in cash or in equal annual installments in cash (calculated as set forth in
Section 7.1(a)(6)) over a period of from two (2) up to fifteen (15) years beginning on the
Participant’s Payment Date.

(3) A Participant may elect to change the Scheduled In-Service Withdrawal Date for the
Withdrawal Amount for any Plan Year in accordance with Section 3.2(d).

(4) In the event of Participant’s Separation from Service or Disability prior to a Scheduled
In-Service Withdrawal Date, the Participant’s entire Withdrawal Amount shall be paid in accordance
with the Participant’s election with respect to such Plan Year under Section 7.1(a).

(c) Distribution upon Death. In the event a Participant dies, any remaining balance in his
Accounts shall be paid to his Beneficiary in a lump sum in cash on the first business day of the
seventh calendar month following the date of the Participant’s death.

7.2 Hardship Distribution.

A Participant shall be permitted to elect a Hardship Distribution of all or a portion of his
Accounts under the Plan prior to the Payment Date, subject to the following restrictions:

(a) The election to take a Hardship Distribution shall be made by filing the form provided by
the Committee before the date established by the Committee.

(b) The Committee shall have made a determination that the requested distribution constitutes
a Hardship Distribution in accordance with subsection (d).

(c) The amount determined by the Committee as a Hardship Distribution shall be paid in a
single lump sum in cash as soon as practicable after the end of the calendar month in which the
Hardship Distribution election is made and approved by the Committee. The Hardship Distribution
shall be distributed proportionately from the subaccounts in the Participant’s Accounts.

(d) If a Participant receives a Hardship Distribution, the Participant shall be ineligible to
contribute deferrals to the Plan for the following Plan Year. “Hardship Distribution” shall mean a
severe financial hardship to the Participant resulting from (i) an illness or accident of the
Participant, the Participant’s spouse or of his dependent (as defined in Section 152(a) of the
Code), (ii) loss of a Participant’s property due to casualty, or (iii) other similar extraordinary
and unforeseeable circumstances arising as a result of events beyond the control of the
Participant, as determined by the Committee in accordance with Section 409A(a)(2)(B)(ii)(I) of the
Code and the Treasury Regulations thereunder. The amount of the Hardship Distribution with
respect to a severe financial hardship shall not exceed the amounts necessary to satisfy such
hardship, plus amounts necessary to pay taxes reasonably anticipated as a result of the
distribution, after taking into account the extent to which such hardship is or may be relieved
through reimbursement or compensation by insurance or otherwise or by liquidation of the
Participant’s assets (to the extent the liquidation of such assets would not itself cause severe
financial hardship), as determined by the Committee in accordance with Section
409A(a)(2)(B)(ii)(II) of the Code and the Treasury Regulations thereunder.

7.3 Effect of a Change in Control.

(a) In the event there is a Change in Control, the person who is the chief executive officer
(or, if not so identified, the Company’s highest ranking officer) shall name a third-party
fiduciary as the sole member of the Committee immediately prior to such Change in Control. The
appointed fiduciary, shall oversee the administration of the Plan and provide for the distributions
of the accounts under the Plan in accordance with the terms of the Plan and the elections of the
Participants.

(b) Upon and after the occurrence of a Change in Control, the Company must (i) pay all
reasonable administrative fees and expenses of the appointed fiduciary, (ii) indemnify the
appointed fiduciary against any costs, expenses and liabilities including, without limitation,
attorney’s fees and expenses arising in connection with the appointed fiduciary’s duties hereunder,
other than with respect to matters resulting from the gross negligence of the appointed fiduciary
or its agents or employees and (iii) timely provide the appointed fiduciary with all necessary
information related to the Plan, the Participants and Beneficiaries.

(c) Notwithstanding Section 9.4, in the event there is a Change in Control no amendment may be
made to this Plan except as approved by the third-party fiduciary. Upon a Change in Control, the
Company shall establish an irrevocable trust and contribute assets to such trust in an amount equal
to the aggregate amount credited to the Participants’ Accounts, as determined by the appointed
fiduciary, plus any deferred payments as they are deferred by the Participants. Such trust shall
conform to the model “rabbi trust” agreement provided by the Internal Revenue Service in Revenue
Procedure 92-64, as revised from time to time, and shall be structured as an unfunded arrangement.

7.4 Inability to Locate Participant.

In the event that the Committee is unable to locate a Participant or Beneficiary within two
years following the required Payment Date, the amount allocated to the Participant’s Accounts shall
be forfeited. If, after such forfeiture, the Participant or Beneficiary later claims such benefit,
such benefit shall be reinstated without interest or earnings from the date of forfeiture, subject
to applicable escheat laws.

7.5 Prohibition on Acceleration of Distributions.

The time or schedule of payment of any withdrawal or distribution under the Plan shall not be
subject to acceleration, except as provided under Treasury Regulations promulgated in accordance
with Section 409A(a)(3) of the Code.

ARTICLE VIII.

ADMINISTRATION

8.1 Committee. The Committee shall administer the Plan in accordance with this Article.

8.2 Administrator.

The Administrator, unless restricted by the Committee, shall exercise the powers under
Sections 8.4 and 8.5 except when the exercise of such authority would materially affect the cost of
the Plan to the Company or materially increase benefits to Participants.

8.3 Committee Action.

The Committee shall act at meetings by affirmative vote of a majority of the members of the
Committee. Any action permitted to be taken at a meeting may be taken without a meeting if, prior
to such action, a written consent to the action is signed by all members of the Committee and such
written consent is filed with the minutes of the proceedings of the Committee. A member of the
Committee shall not vote or act upon any matter which relates solely to himself or herself as a
Participant. The chairman or any other member or members of the Committee designated by the
chairman may execute any certificate or other written direction of behalf of the Committee.

8.4 Powers and Duties of the Committee.

(a) The Committee, on behalf of the Participants and their Beneficiaries, shall enforce the
Plan in accordance with its terms, shall be charged with the general administration of the Plan,
and shall have all powers necessary to accomplish its purposes as set forth herein, including, but
not by way of limitation, the following:

(1) To select the Measurement Funds in accordance with Section 4.1 hereof;

(2) To construe and interpret the terms and provisions of the Plan and to remedy any
inconsistencies or ambiguities hereunder;

(3) To select employees eligible to participate in the Plan;

(4) To compute and certify to the amount and kind of benefits payable to Participants and
their Beneficiaries;

(5) To maintain all records that may be necessary for the administration of the Plan;

(6) To provide for the disclosure of all information and the filing or provision of all
reports and statements to Participants, Beneficiaries or governmental agencies as shall be required
by law;

(7) To make and publish such rules for the regulation of the Plan and procedures for the
administration of the Plan as are not inconsistent with the terms hereof;

(8) To appoint a plan administrator or any other agent, and to delegate to them such powers
and duties in connection with the administration of the Plan as the Committee may from time to time
prescribe; and

(9) To take all actions necessary for the administration of the Plan.

8.5 Delegation of Authority

To the extent permitted by applicable law, the Committee may from time to time delegate to a
committee of one or more members of the Board or one or more executives or employees of the Company
its powers and duties under the Plan, including its power and authority under Section 9.4. Any
delegation hereunder shall be subject to the restrictions and limits that the Committee specifies
at the time of such delegation, and the Committee may at any time rescind the authority so
delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 8.5
shall serve in such capacity at the pleasure of the Committee.

8.6 Construction and Interpretation.

The Committee shall have full discretion to construe and interpret the terms and provisions of
this Plan, which interpretations or construction shall be final and binding on all parties,
including but not limited to the Company and any Participant or Beneficiary. The Committee shall
administer such terms and provisions in a uniform and nondiscriminatory manner and in full
accordance with any and all laws applicable to the Plan.

8.7 Information.

To enable the Committee to perform its functions, the Company shall supply full and timely
information to the Committee on all matters relating to the Compensation of all Participants, their
death or other events which cause termination of their participation in this Plan, and such other
pertinent facts as the Committee may require.

8.8 Compensation, Expenses and Indemnity.

(a) The members of the Committee shall serve without compensation for their services
hereunder.

(b) The Committee is authorized at the expense of the Company to employ such legal counsel and
other advisors as it may deem advisable to assist in the performance of its duties hereunder.
Expenses and fees in connection with the administration of the Plan shall be paid by the Company.

(c) To the extent permitted by applicable state law, the Company shall indemnify and save
harmless the Committee and each member thereof, the Board of Directors and any delegate of the
Committee who is an employee of the Company against any and all expenses, liabilities and claims,
including legal fees to defend against such liabilities and claims arising out of their discharge
in good faith of responsibilities under or incident to the Plan, other than expenses and
liabilities arising out of willful misconduct. This indemnity shall not preclude such further
indemnities as may be available under insurance purchased by the Company or provided by the Company
under any bylaw, agreement or otherwise, as such indemnities are permitted under state law.

8.9 Quarterly Statements.

Under procedures established by the Committee, a Participant shall receive a statement with
respect to such Participant’s Accounts on a quarterly basis as of each March 31, June 30, September
30 and December 31.

8.10 Disputes.

(a) Claim.

A person who believes that he is being denied a benefit to which he is entitled under this
Agreement (hereinafter referred to as “Claimant”) may file a written request for such benefit with
the Administrator, setting forth his claim. The request must be addressed to the Administrator at
the Company at its then principal place of business.

(b) Claim Decision.

Upon receipt of a claim, the Administrator shall advise the Claimant that a reply shall be
forthcoming within 90 days and shall, in fact, deliver such reply within such period. The
Administrator may, however, extend the reply period for an additional 90 days for special
circumstances.

If the claim is denied in whole or in part, the Administrator shall inform the Claimant in
writing, using language calculated to be understood by the Claimant, setting forth: (i) the
specified reason or reasons for such denial; (ii) the specific reference to pertinent provisions of
this Agreement on which such denial is based; (iii) a description of any additional material or
information necessary for the Claimant to perfect his claim and an explanation of why such material
or such information is necessary; (iv) appropriate information as to the steps to be taken if the
Claimant wishes to submit the claim for review; and (v) the time limits for requesting a review
under subsection (c).

(c) Request For Review.

Within 60 days after the receipt by the Claimant of the written decision described above, the
Claimant may request in writing a review the determination of the Administrator. Such review shall
be completed by the Committee. Such request must be addressed to the Secretary of the Company, at
its then principal place of business. The Claimant or his duly authorized representative may, but
need not, review the pertinent documents and submit issues and comments in writing for
consideration by the Committee. If the Claimant does not request a review within such 60-day
period, he shall be barred and estopped from challenging the Administrator’s determination.

(d) Review of Decision.

Within 60 days after the receipt of a request for review by the Committee, as applicable,
after considering all materials presented by the Claimant, the Committee shall inform the
Participant in writing, in a manner calculated to be understood by the Claimant, the decision
setting forth the specific reasons for the decision contained specific references to the pertinent
provisions of this Plan on which the decision is based. If special circumstances require that the
60 day time period be extended, the Committee, as applicable, shall so notify the Claimant and
shall render the decision as soon as possible, but no later than 120 days after receipt of the
request for review.

	8.11	 	Compliance with Section 409A of the Code.

The Plan shall be interpreted, construed and administered in a manner that satisfies the
requirements of Sections 409A(a)(2), (3) and (4) of the Code and the Treasury Regulations
thereunder.

ARTICLE IX.

MISCELLANEOUS

9.1 Unsecured General Creditor.

Participants and their Beneficiaries, heirs, successors, and assigns shall have no legal or
equitable rights, claims, or interest in any specific property or assets of the Company. No assets
of the Company shall be held in any way as collateral security for the fulfilling of the
obligations of the Company under this Plan. Any and all of the Company’s assets shall be, and
remain, the general unpledged, unrestricted assets of the Company. The Company’s obligation under
the Plan shall be merely that of an unfunded and unsecured promise of the Company to pay money in
the future, and the rights of the Participants and Beneficiaries shall be no greater than those of
unsecured general creditors. It is the intention of the Company that this Plan be unfunded for
purposes of the Code and Title I of ERISA.

9.2 Restriction Against Assignment.

(a) The Company shall pay all amounts payable hereunder only to the person or persons
designated by the Plan and not to any other person or entity. No right, title or interest in the
Plan or in any account may be sold, pledged, assigned or transferred in any manner other than by
will or the laws of descent and distribution. No right, title or interest in the Plan or in any
Account shall be liable for the debts, contracts or engagements of the Participant or his
successors in interest or shall be subject to disposition by transfer, alienation, anticipation,
pledge, encumbrance, assignment or any other means whether such disposition be voluntary or
involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or
equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null
and void and of no effect, except to the extent that such disposition is permitted by the preceding
sentence.

(b) Notwithstanding the provisions of subsection (a), a Participant’s interest in his Account
may be transferred by the Participant pursuant to a domestic relations order that constitutes a
“qualified domestic relations order” as defined by the Code or Title I of ERISA.

9.3 Withholding.

There shall be deducted from each payment made under the Plan or any other Compensation
payable to the Participant (or Beneficiary) all taxes which are required to be withheld by the
Company in respect to such payment or this Plan. The Company shall have the right to reduce any
payment (or compensation) by the amount of such of cash sufficient to provide the amount of said
taxes.

9.4 Amendment, Modification, Suspension or Termination.

(a) Subject to Section 7.3, the Committee may amend, modify, suspend or terminate the Plan in
whole or in part, except that no amendment, modification, suspension or termination shall have any
retroactive effect to reduce any vested amounts allocated to a Participant’s Accounts. In the event
of Plan termination, distributions shall continue to be made in accordance with the terms of the
Plan.

(b) Notwithstanding anything to the contrary in the Plan, if and to the extent the Company
shall determine that the terms of the Plan may result in the failure of the Plan, or amounts
deferred by or for any Participant under the Plan, to comply with the requirements of Section 409A
of the Code, or any applicable regulations or guidance promulgated by the Secretary of the Treasury
in connection therewith, the Company shall have authority to take such action to amend, modify,
cancel or terminate the Plan or distribute any or all of the amounts deferred by or for a
Participate, as it deems necessary or advisable, including without limitation:

(1) Any amendment or modification of the Plan to conform the Plan to the requirements of
Section 409A of the Code or any regulations or other guidance thereunder (including, without
limitation, any amendment or modification of the terms of any applicable to any Participant’s
Accounts regarding the timing or form of payment).

(2) Any cancellation or termination of any unvested interest in a Participant’s Accounts
without any payment to the Participant.

(3) Any cancellation or termination of any vested interest in any Participant’s Accounts, with
immediate payment to the Participant of the amount otherwise payable to such Participant.

Any such amendment, modification, cancellation, or termination of the Plan may adversely affect the
rights of a Participant without the Participant’s consent.

9.5 Designation of Beneficiary.

(a) Each Participant shall have the right to designate, revoke and redesignate Beneficiaries
hereunder and to direct payment of his Distributable Amount to such Beneficiaries upon his death.

(b) Designation, revocation and redesignation of Beneficiaries must be made in writing in
accordance with the procedures established by the Committee and shall be effective upon delivery to
the Committee.

(c) No designation of a Beneficiary other than the Participant’s spouse shall be valid unless
consented in writing by such spouse. If there is no Beneficiary designation in effect, or the
designated beneficiary does not survive the Participant, then the Participant’s spouse shall be the
Beneficiary. If there is no surviving spouse, the duly appointed and currently acting personal
representative of the Participant’s estate (which shall include either the Participant’s probate
estate or living trust) shall be the Beneficiary.

(d) After the Participant’s death, any Beneficiary (other than the Participant’s estate) who
is to receive installment payments may designate a secondary beneficiary to receive amounts due
under this Plan to the Beneficiary in the event of the Beneficiary’s death prior to receiving full
payment from the Plan. If no secondary beneficiary is designated, it shall be the Beneficiary’s
estate.

9.6 Governing Law.

Subject to ERISA, this Plan shall be construed, governed and administered in accordance with
the laws of the State of California.

9.7 Compliance with Code Section 162(m).

It is the intent of the Company that any Compensation which is deferred under the Plan by a
person who is, with respect to the year of distribution, deemed by the Committee to be a “covered
employee” within the meaning of Code Section 162(m) and regulations thereunder, which Compensation
constitutes either “qualified performance-based compensation” within the meaning of Code Section
162(m) and regulations thereunder or compensation not otherwise subject to the limitation on
deductibility under Section 162(m) and regulations thereunder, shall not, as a result of deferral
hereunder, become compensation with respect to which the Company in fact would not be entitled to a
tax deduction under Code Section 162(m). If the Company determines in good faith prior to a
Change in Control that there is a reasonable likelihood that any compensation paid to a Participant
for a taxable year of the Company would not be deductible by the Company solely by reason of the
limitation under Code Section 162(m), then to the extent deemed necessary by the Committee to
ensure that the entire amount of any distribution to the Participant pursuant to this Plan prior to
the Change in Control is deductible, the Company may defer all or any portion of a distribution
under this Plan. Any amounts deferred pursuant to this limitation shall continue to be
credited/debited with additional amounts in accordance with Article IV, even if such amount is
being paid out in installments. The amounts so deferred and amounts credited thereon shall be
distributed to the Participant or his Beneficiary (in the event of the Participant’s death)
commencing as soon as reasonably practicable following the Plan Year in which such Participant’s
Separation from Service, Disability or Death occurs, or if earlier, the effective date of a Change
in Control. Notwithstanding anything to the contrary in this Plan, this Section shall not apply to
any distributions made after a Change in Control.

9.8 Payments on Behalf of Persons Under Incapacity.

In the event that any amount becomes payable under the Plan to a person who, in the sole
judgment of the Committee, is considered by reason of physical or mental condition to be unable to
give a valid receipt therefore, the Committee may direct that such payment be made to any person
found by the Committee, in its sole judgment, to have assumed the care of such person. Any payment
made pursuant to such termination shall constitute a full release and discharge of the Committee
and the Company.

9.9 Limitation of Rights.

Neither the establishment of the Plan nor any modification thereof, nor the creating of any
fund or account, nor the payment of any benefits shall be construed as giving to any Participant or
other person any legal or equitable right against the Company except as provided in the Plan. In
no event shall the terms of employment of, or membership on the Board by, any Participant be
modified or in any way be effected by the provisions of the Plan.

9.10 Exempt ERISA Plan

The Plan is intended to be an unfunded plan maintained primarily to provide deferred
compensation benefits for a select group of management or highly compensated employees within the
meaning of Sections 201, 301 and 401 of ERISA and therefore to be exempt from Parts 2, 3 and 4 of
Title I of ERISA.

9.11 Notice

Any notice or filing required or permitted to be given to the Committee under the Plan shall
be sufficient if in writing and hand delivered, or sent by registered or certified mail, to the
principal office of the Company, directed to the attention of the General Counsel and Secretary of
the Company. Such notice shall be deemed given as of the date of delivery or, if delivery is made
by mail, as of the date shown on the postmark on the receipt for registration or certification.

9.12 Errors and Misstatements

In the event of any misstatement or omission of fact by a Participant to the Committee or any
clerical error resulting in payment of benefits in an incorrect amount, the Committee shall
promptly cause the amount of future payments to be corrected upon discovery of the facts and shall
pay or, if applicable, cause the Plan to pay, the Participant or any other person entitled to
payment under the Plan any underpayment in a lump sum or to recoup any overpayment from future
payments to the Participant or any other person entitled to payment under the Plan in such amounts
as the Committee shall direct or to proceed against the Participant or any other person entitled to
payment under the Plan for recovery of any such overpayment.

9.13 Pronouns and Plurality

The masculine pronoun shall include the feminine pronoun, and the singular the plural where
the context so indicates.

9.14 Severability

In the event that any provision of the Plan shall be declared unenforceable or invalid for any
reason, such unenforceability or invalidity shall not affect the remaining provisions of the Plan
but shall be fully severable, and the Plan shall be construed and enforced as if such unenforceable
or invalid provision had never been included herein.

9.15 Status

The establishment and maintenance of, or allocations and credits to, the Accounts of any
Participant shall not vest in any Participant any right, title or interest in and to any Plan
assets or benefits except at the time or times and upon the terms and conditions and to the extent
expressly set forth in the Plan.

9.16 Headings.

Headings and subheadings in this Plan are inserted for convenience of reference only and are
not to be considered in the construction of the provisions hereof.

3EX-10.1

Exhibit 10.1

TECHNOLOGY AND INTELLECTUAL PROPERTY AGREEMENT

between

CELL GENESYS, INC.

and

GBP IP, LLC

Dated as of December 19, 2007

1

TECHNOLOGY AND INTELLECTUAL PROPERTY AGREEMENT

THIS TECHNOLOGY AND INTELLECTUAL PROPERTY AGREEMENT (this “Agreement”) is dated as of
December 19, 2007 (the “Effective Date”), by and between Cell Genesys, Inc., a Delaware
corporation, with its principal place of business at 500 Forbes Boulevard, South San Francisco,
California 94080 (“CGI”), and GBP IP, LLC, a Delaware limited liability company, with its
principal place of business at 537 Steamboat Road, Greenwich, CT 06830 (“GBP”), (each, a
“Party” and, collectively, the “Parties”).

W I T N E S S E T H:

WHEREAS, CGI owns or has rights in certain lentiviral and retroviral intellectual property and
certain related technology and know-how (including certain biological materials);

WHEREAS, subject to the terms and conditions set forth in this Agreement, CGI agrees to
convey, provide or license such lentiviral and retroviral intellectual property and certain related
technology and know-how (including certain biological materials) to GBP;

WHEREAS, GBP has been formed and is wholly owned by Greenwich Biotech Management LLC, a
Delaware limited liability company having an address at 537 Steamboat Road, Suite 200, Greenwich,
Connecticut 06830, for the purpose obtaining such lentiviral and retroviral intellectual property
and related technology and know-how under the terms of this Agreement;

WHEREAS, one or more of the partners of Greenwich Biotech Management LLC sit on the Board of
Directors of Lentigen Corporation having an address at 1450 South Rolling Road, Baltimore, Maryland
21227; and

WHEREAS, subject to the terms and conditions set forth in this Agreement, GBP agrees to grant
a license back to CGI under certain of the intellectual property rights being transferred to it by
CGI pursuant to this Agreement.

NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements set forth
herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the Parties agree as follows:

ARTICLE I

DEFINITIONS

1.1 Definitions. The following terms, as used in this Agreement, have the following
meanings. All other capitalized terms used herein shall have the meaning as provided in the body
of this Agreement:

“Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly through one or more intermediaries, controls, or is controlled by, or is under common
control with, such Person, and the term “control” (including the terms “controlled by” and “under
common control with”) means the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of such Person, whether through ownership of voting
securities, by contract or otherwise.

“Acquired IP” means the Patents listed on Exhibit A and all Patents that claim
priority benefit to the Patents listed on Exhibit A, including any continuations,
continuations-in-part, divisionals, substitutions, reissues, renewals, extensions or modifications
for any of the foregoing, and all foreign counterparts thereof. For the avoidance of doubt,
Acquired IP shall not include any Intellectual Property Rights licensed to CGI by a Third Party.

“Ceregene Agreement” means the Amended and Restated Technology Transfer Agreement,
effective August 3, 2004, between CGI and Ceregene, Inc., as amended by those certain Side Letters
dated August 3, 2004, August 19, 2005 and January 9, 2007.

“Ceregene Consent” means the consent letter attached hereto as Exhibit C.

“CGI’s Knowledge” means the actual knowledge as of the Effective Date of any member of
CGI’s management team or any member of CGI’s executive committee.

“Disclosing Party” shall have the meaning as indicated in Section 8.1.

“Fee” shall have the meaning as indicated in Section 7.1.

“Indemnitee” shall have the meaning as indicated in Section 9.3.

“Intellectual Property Rights” or “IPRs” means the rights associated with any
of the following anywhere in the world: (i) patents and patent applications therefor (including any
continuations, continuations-in-part, divisionals, substitutions, reissues, renewals, extensions or
modifications for any of the foregoing, and all foreign counterparts thereof) (“Patents”);
(ii) trade secrets, know-how and all other rights in or to confidential business or technical
information (“Trade Secrets”); (iii) copyrights, copyright registrations and applications
therefor, moral rights and all other rights corresponding to the foregoing (“Copyrights”);
(iv) trademarks and service marks, whether registered or unregistered, and the goodwill appurtenant
to each of the foregoing (“Trademarks”); and (v) any similar, corresponding or equivalent
rights to any of the foregoing. “Intellectual Property Rights” do not include any
Technology.

“Licensed Field” means all fields except cancer immunotherapies.

“Licensed Product” means any lentiviral or retroviral product whose manufacture, use
or sale would, but for the license to be granted under Section 3.1 of this Agreement, infringe a
Valid Claim (as defined in the MIT Agreement) of any Patent within the Whitehead Patent Rights.

“Liens” means any security interest, pledge, hypothecation, mortgage, lien or
encumbrance, other than any license of Intellectual Property Rights.

“MIT Agreement” means the Amended and Restated Exclusive Patent License Agreement by
and among CGI, Massachusetts Institute of Technology and Whitehead Institute for Biomedical
Research, dated December 17, 1998, as amended by First Amendment dated September 27, 2005.

“Out-Licenses” means those licenses of Acquired IP or SALK IP Rights by CGI to a Third
Party specifically listed on Exhibit D, including all amendments and modifications thereto.

“Part II Patent Rights” means, with respect to the Ceregene Agreement, the Acquired IP
and SALK IP Rights specifically listed and described in Exhibit A Part II of the Side Letter dated
January 9, 2007 that is part of the Ceregene Agreement.

“Person” means any individual, corporation, partnership, firm, joint venture,
association, joint-stock company, limited liability company, limited liability partnership, labor
union, trust, unincorporated organization, governmental body or other entity.

“Proprietary Information” shall have the meaning as indicated in Section 8.1.

“Provided Technology” means the Technology listed and described on Exhibit B.

“Receiving Party” shall have the meaning as indicated in Section 8.1.

“SALK Agreement” means the Amended and Restated License Agreement, effective as of
December 10, 2000, between the SALK Institute for Biological Studies and CGI.

“SALK IP Rights” means the rights to the Patents listed on Exhibit E granted
under the SALK Agreement to Licensee (as defined in the SALK Agreement).

“Taxes” shall have the meaning as indicated in Section 7.3.

“Technology” means any and all tangible embodiments of Intellectual Property Rights,
including chemical compounds and formulations, chemical or biological solutions, gene, nucleic acid
or amino acid sequence information, genetic or protein libraries, DNA, RNA, proteins, enzymes,
antibodies, probes, plasmids, vectors, expression vectors and systems, cells, cell lines, cell
banks, cell cultures, transformed hosts, tissues and other biological materials or information
pertaining thereto together with any and all progeny, mutants and replications of such materials,
and any and all constituents and derivatives of such materials, software, designs, formulae,
procedures, methods, screening and selection processes and technologies, assays, analytical tests,
techniques, ideas, know-how, research and development and technical data, programs, tools,
specifications, processes, apparatus, and all documentation, recordings, graphs, drawings, reports,
analyses, and other writings describing or embodying the above (whether in tangible or electronic
form). “Technology” does not include Intellectual Property Rights, including any
Intellectual Property Rights in any of the foregoing.

“Third Party” means any Person other than a Party or their respective Affiliates.

“Whitehead Patent Rights” means the rights that CGI receives under the MIT Agreement
to the Patents listed on Exhibit F.

ARTICLE II

ASSIGNMENT AND TRANSFER

OF RIGHTS AND TECHNOLOGY

2.1 Assignment of Intellectual Property Rights and Agreements. Subject to the terms
and conditions of this Agreement (including without limitation full payment under Article VII and
the execution of the Ceregene Consent), CGI hereby sells, assigns, and transfers to GBP the
following:

(a) all right, title and interest in and to the Acquired IP;

(b) the SALK Agreement, subject to the terms and conditions of the SALK Agreement; and

(c) the Out-Licenses, subject to the terms and conditions of each Out-License;
provided however, that with respect to the Ceregene Agreement, CGI hereby
sells, assigns, and transfers to GBP only those portions of the Ceregene Agreement as they
relate to the Part II Patent Rights.

For the avoidance of doubt, upon the assignment and conveyance of the Out-Licenses and the SALK
Agreement to GBP, GBP shall replace CGI as a party to each Out-License and the SALK Agreement and
shall succeed to all of the rights and assume all of the responsibilities of CGI under each such
Out-License and the SALK Agreement as of the Effective Date, except that, with respect to the
Ceregene Agreement, GBP shall only succeed to the rights and assume the responsibilities of CGI as
they relate to the Part II Patent Rights. GBP acknowledges and agrees that, as of and after the
Effective Date, CGI shall have no further duties or obligations under the Out-Licenses (or the
applicable portion of the Ceregene Agreement) or the SALK Agreement, and GBP shall assume and be
solely responsible for all such duties and obligations on a forward going basis.

2.2 Transfer of Technology. In connection with the assignment described in Section
ý2.1, CGI shall provide and/or deliver to GBP:

(a) as soon as commercially practical after the Effective Date, but in any event no
later than thirty (30) days after the Effective Date, a one-time provision of the Provided
Technology. In connection with the foregoing and upon delivery, CGI grants to GBP a
perpetual, unrestricted, non-exclusive, royalty-free license (with the right to grant
sublicenses) to CGI’s Copyrights and Trade Secrets in and to the Provided Technology. For
the avoidance of doubt, the transfer of Provided Technology shall not include the transfer
of any Intellectual Property Rights in addition to the Acquired IP; and

(b) during the six (6) month period after the Effective Date, CGI shall, upon
reasonable request by GBP or its designee, provide to GBP or its designee up to a maximum of
twenty (20) hours of e-mail and telephone support, without further charge, to answer
questions and provide advice and expertise related to the Out-Licenses, Provided Technology
and the Technology covered by the Acquired IP and the SALK IP Rights. The estimated fair
market value of such support services is USD$105 per hour. If GBP or its designee require
more than the twenty (20) hour maximum of e-mail and telephone support during the six (6)
month period or require any such support after that period, then the Parties will enter into
good faith negotiations for a separate services agreement for such support at commercially
reasonable terms.

2.3 No Assumption of Past Liabilities. Notwithstanding anything herein to the
contrary, GBP shall not assume any liability of CGI relating to any fact, circumstance, occurrence,
condition, act, event or omission occurring, or the underlying cause of which occurred, prior to
the Effective Date, whether or not in connection with the Acquired IP, Provided Technology, SALK
Agreement or Out-Licenses.

2.4 No Responsibility for Liabilities. Notwithstanding anything herein to the
contrary, CGI shall not be responsible for and will not assume any liability of GBP or any of its
Affiliates relating to any fact, circumstance, occurrence, condition, act, event or omission
occurring, or the underlying cause of which occurs, on or after the Effective Date, whether or not
in connection with the Acquired IP, Provided Technology, SALK Agreement or Out-Licenses.

ARTICLE III

OPTION TO GBP

3.1 Whitehead Patent Rights. Within ninety (90) days after the Effective Date and
upon written request by GBP, CGI agrees to negotiate with GBP in good faith to grant a
non-exclusive, non-transferable (except in connection with the sale of all or substantially all of
GBP’s business relating to the Whitehead Patent Rights), royalty-bearing (only to the extent such
royalties are owned under the MIT Agreement), worldwide sublicense under the Whitehead Patent
Rights to develop, make, use, sell, offer to sell, lease and import Licensed Products in the
Licensed Field. Such license shall be free of charge to GBP, other than to the extent of any
royalty owed to the licensors under the MIT Agreement. The license granted to GBP will only be
sublicensable: (i) by GBP within the scope of GBP’s license described above and (ii) solely to an
Affiliate of GBP or Third Parties providing services directly to GBP or for the benefit of GBP;
provided that (x) any such sublicense shall not be further sublicensable; and (y)
any such sublicense shall be subject to a written agreement with terms that are consistent with,
and no less protective of CGI or its licensors than the terms of the sublicense granted to GBP.
Furthermore, any such sublicense will contain additional reasonable and customary terms for a
license of this nature and shall be subject to all of the terms and conditions set forth in the MIT
Agreement with respect to sublicenses.

ARTICLE IV

LICENSES TO CGI

4.1 Grant-back License. GBP hereby grants CGI and its Affiliates a fully paid-up,
non-exclusive, perpetual, non-transferable (except in connection with the sale of all or
substantially all of CGI’s business utilizing the applicable technology), royalty-free, worldwide
license under the Acquired IP and SALK IP Rights to use any inventions or methods disclosed or
claimed therein for its own internal research and development purposes. For the avoidance of
doubt, under the foregoing license CGI and its Affiliates shall have the right to use the Acquired
IP and SALK IP Rights in order to insert nucleic acids into cancer cells for development of cancer
immunotherapies for commercialization (e.g., GVAXTM immunotherapies); provided that CGI shall not
use the Acquired IP or SALK IP Rights to (i) commercialize any lentiviral particle or (ii)
commercially manufacture any product.

4.2 Sublicenses. The license to CGI described in Section ý4.1 shall not
include any right to grant any sublicenses, except that CGI may grant sublicenses to its
subcontractors for the sole limited purpose of conducting activities authorized under Section 4.1
on behalf of and for the benefit of CGI and its Affiliates. In the event that a subcontractor is
granted such rights, the subcontractor may exercise such rights at facilities owned and operated by
the subcontractor.

4.3 2A Furin Technology. Upon CGI’s written request, GBP agrees to negotiate in good
faith to license the Acquired IP to a Third Party as necessary for such Third Party to exploit
CGI’s 2A Furin technology for in vitro antibody production.

4.4 Termination by GBP. GBP may terminate in whole or in part the license granted
pursuant to this ýArticle IV as to CGI or any Affiliate or any sub-licensee of CGI if CGI
or such Affiliate or sub-licensee is in material breach of any provision of ýArticle IV
or ýArticle VIII hereof by giving CGI thirty (30) days prior written notice of such
termination, provided, however, that if CGI (or, if applicable, such Affiliate or
sub-licensee) cures the breach within such thirty (30) day period, then the license granted
pursuant to this ýArticle IV will remain in effect and in force as if no breach had
existed.

ARTICLE V

REPRESENTATIONS AND WARRANTIES

5.1 General Warranties. Each Party represents and warrants to the other Party that,
subject to the execution of the Ceregene Consent:

(a) it has the power and authority to execute and deliver this Agreement and to perform
the acts required of it hereunder,

(b) the execution, delivery and performance of this Agreement by such Party has been
duly authorized by all requisite corporate action, and this Agreement constitutes such
Party’s legal, valid and binding obligation enforceable against it in accordance with its
terms, and

(c) the execution, delivery and performance of this Agreement does not, as of the
Effective Date, (i) violate, conflict with or result in the breach of any provision of its
certificate of incorporation, operating agreement or by laws, (ii) violate any law,
governmental regulation or governmental order applicable to it or any of its assets,
properties or businesses, or (iii) result in any breach of, constitute a default (or event
which with the giving of notice or lapse of time, or both, would become a default) under, or
require any consent (except, with respect to CGI, the Ceregene Consent) under any contract,
agreement or arrangement by which it is bound.

5.2 Representations and Warranties of GBP. GBP represents and warrants, as of the
Effective Date:

(a) Good Standing. GBP is a limited liability company duly organized, validly
existing and in good standing under the laws of the State of Delaware and has all requisite
power and authority to own, lease and operate its properties and to carry on its business as
currently conducted.

(b) Adequate Resources. GBP has adequate financial resources to satisfy its
monetary and other obligations under this Agreement, and has adequate personnel resources or
ability to perform, or cause to be performed, its obligations under this Agreement and under
the SALK Agreement and the Out-Licenses.

(c) GBP Due Diligence. GBP acknowledges that, except for the matters that are
expressly covered by the provisions of this Agreement, it is relying on its own
investigation and analysis in entering into this Agreement and the transactions contemplated
hereby. GBP is an informed and sophisticated participant in the transactions contemplated
hereby and has undertaken such investigation, and has been provided with and has evaluated
such documents and information, as it has deemed necessary in connection with the execution,
delivery and performance of this Agreement. GBP acknowledges that it is consummating the
transactions contemplated hereby without any representation or warranty, express or implied,
by CGI except as expressly set forth herein.

5.3 Representations and Warranties of CGI. CGI represents and warrants, as of the
Effective Date, subject to the execution of the Ceregene Consent:

(a) Ownership. CGI exclusively owns all right, title and interest in and to
each item of Acquired IP, free and clear of all Liens.

(b) Intellectual Property Rights. To CGI’s Knowledge, the issued Patents
constituting the Acquired IP and the SALK IP Rights are valid, subsisting and enforceable
(except, for avoidance of doubt, any Patents in Exhibit A or Exhibit E
identified therein as having expired under the applicable statutory or national filing
deadline). The Acquired IP and, to CGI’s Knowledge, the SALK IP Rights are not subject to
any outstanding order, judgment, injunction, decree or ruling adversely affecting CGI’s
rights thereto. The Acquired IP is currently in compliance with any and all formal legal
requirements necessary to record and perfect CGI’s interest therein and the chain of title
thereof. Other than as part of patent prosecution matters in the ordinary course, (i) there
is no action or claim pending, asserted or, to CGI’s Knowledge, threatened against CGI
concerning the ownership, validity, registerability, or enforceability of any Acquired IP
or, to CGI’s Knowledge, the SALK IP Rights, and (ii) CGI has not received any written
notification of any action or claim contesting or challenging the ownership, validity,
registerability or enforceability of any Acquired IP or the SALK IP Rights.

(c) Infringement. To CGI’s Knowledge, the use of or the practice of the
inventions claimed in the Acquired IP and SALK IP Rights does not infringe or misappropriate
the valid Intellectual Property Rights of any Third Party. CGI has not received any written
notification that CGI’s practice of the inventions claimed in the Acquired IP or SALK IP
Rights infringes or misappropriates the valid Intellectual Property Rights of any Third
Party, and there is no action or claim pending, asserted or, to CGI’s Knowledge, threatened
against CGI concerning the foregoing. To CGI’s Knowledge, no Third Party is engaging in any
activity that infringes or misappropriates the Acquired IP or SALK IP Rights, and there is
no action or claim pending, asserted or threatened by CGI against any Third Party concerning
the foregoing.

(d) Licenses. Exhibit D sets forth a true and complete list of all
licenses of any Acquired IP or SALK IP Rights by CGI to any Third Party. CGI has furnished
to GBP prior to the execution and delivery of this Agreement true and complete copies of all
Out-Licenses and the SALK Agreement. Other than the rights and assets transferred or
provided under Article II of this Agreement, there are no other Intellectual Property Rights
owned or controlled by CGI as of the Effective Date in which an entity having personnel
reasonably skilled in lentiviral technology must possess in order to succeed to the rights
of CGI under the Out-Licenses (or applicable portion of the Ceregene Agreement) and the SALK
License and assume all the responsibilities of CGI thereunder without breach thereof. There
are no existing breaches or defaults by CGI or, to CGI’s Knowledge, any other party to any
of the SALK Agreement or the Out-Licenses (except, with respect to the breach by Genetix
Pharmaceuticals, Inc. of Article 5 under the Non-Exclusive License and Sub-License Agreement
between Genetix Pharmaceuticals, Inc. and CGI, effective as of November 1, 2005), and, to
CGI’s Knowledge, no event has occurred which (with notice, lapse of time or both) could
reasonably be expected to constitute a breach or default under any such agreement by any
party thereto (except, with respect to Genetix Pharmaceuticals, Inc. as noted above), or
give any such party the right to terminate, accelerate or modify any such agreement.

(e) Effect of Transaction. The consummation of the transactions contemplated
by this Agreement will not result in (i) the creation of any Lien on any Acquired IP, SALK
IP Rights or any Intellectual Property Rights owned by or licensed to GBP or any of its
Affiliates prior to the Effective Date, (ii) GBP or any of its Affiliates being bound by or
subject to (other than under the Out-Licenses) any non-compete or licensing obligation,
covenant not to sue, or other restriction on the operation or scope of its business, which
GBP or its Affiliates were not bound by or subject to prior to the Effective Date, or (iii)
the termination, abandonment or expiration of any Acquired IP, SALK IP Rights or any
Intellectual Property Rights owned by or licensed to GBP prior to the Effective Date; in
each case of (i), (ii) and (iii), except as a result of GBP’s or its Affiliates’ agreements,
licenses or other obligations existing as of the Effective Date.

5.4 Warranties Disclaimer. Except as otherwise set forth herein, (i) EACH PARTY
ACKNOWLEDGES AND AGREES THAT ALL INTELLECTUAL PROPERTY RIGHTS AND TECHNOLOGY TRANSFERRED OR
LICENSED OR SERVICES PROVIDED HEREUNDER ARE PROVIDED WITHOUT ANY ADDITIONAL WARRANTIES WHATSOEVER,
WHETHER EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT THERETO, INCLUDING WITHOUT LIMITATION ANY
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, ENFORCEABILITY OR
NON-INFRINGEMENT, (ii) neither Party makes any warranty or representation that any manufacture,
use, importation, offer for sale or sale of any product or service covered by any Intellectual
Property Rights transferred or licensed under this Agreement will be free from infringement of any
patent or other Intellectual Property Right of any Third Party, and (iii) CGI does not make any
warranty or representation as to the validity and/or scope of the Acquired IP or SALK IP Rights.

ARTICLE VI

ADDITIONAL RELATED MATTERS

6.1 MIT Agreement. During the period in which GBP may exercise the option under
Section 3.1 and while the Parties are engaged in any related good faith negotiations thereunder,
CGI shall perform, in all material respects, its obligations under to the MIT Agreement, and CGI
will not, through any act or omission cause any breach or default under, or otherwise cause the
termination or amendment of, the MIT Agreement such that CGI cannot grant GBP such sublicense.

6.2 GBP’s Guarantor. Greenwich Biotech Management LLC shall, on behalf of itself and
its Affiliates, act as a guarantor of GBP and GBP’s Affiliates’ performance under this Agreement
and shall be responsible and liable for all liabilities, obligations and duties of GBP and GBP’s
Affiliates hereunder including, without limitation, any obligation under the SALK Agreement or
Out-Licenses after the Effective Date, GBP’s payment obligations under Article VII, and GBP’s
indemnification obligations under Article IX. Greenwich Biotech Management LLC has adequate
financial resources to satisfy GBP and GBP’s Affiliates’ monetary and other obligations under this
Agreement. Notwithstanding the foregoing, in no event shall Greenwich Biotech Management LLC or
any of its Affiliates be deemed a third party beneficiary under this Agreement for any reason.

6.3 Patent Assignment Agreement. In connection with the assignment of the Acquired IP
pursuant to the terms and conditions of Section 2.1(a), the Parties shall execute a “Patent
Assignment Agreement” in a form substantially similar to that attached hereto as Exhibit
G to document the transfer of the Acquired IP. GBP shall have the sole responsibility, at its
sole cost and expense, to file the Patent Assignment Agreement and any other forms or documents as
required to record the assignment of the Acquired IP from CGI to GBP with the United States Patent
and Trademark Office and any applicable foreign equivalents; provided, however,
that, upon request, CGI shall provide reasonable assistance to GBP to record the assignment, at
GBP’s sole cost and expense. As of the Effective Date, as between the Parties, GBP shall be solely
responsible for maintaining (including prosecution and payment of all fees) and enforcing the
Acquired IP.

6.4 Press Release. Except for the press release contained in Exhibit H, none
of the Parties to this Agreement shall make, or cause to be made, any press release or public
announcement in respect of this Agreement or the transactions contemplated by this Agreement or
otherwise communicate with any news media without the prior written consent of the other Party
unless such press release or public announcement is required by applicable law or applicable stock
exchange regulation, in which case the Parties to this Agreement shall, to the extent practicable,
consult with each other as to the timing and contents of any such press release, public
announcement or communication.

6.5 Retroviral/Lentiviral Assets. Subject to the execution of the Ceregene Consent,
CGI agrees that the consummation of the transactions contemplated by this Agreement constitutes the
sale or transfer by CGI to GBP of all or substantially all assets owned or controlled by CGI
immediately prior to the Effective Date (i) required for making or using first, second, and third
generation lentiviral vectors to make lentiviral particles, in each case, solely as claimed in the
issued Patents constituting the Acquired IP or the SALK IP Rights, and (ii) to which the SALK
Agreement and each Out-License relates.

6.6 SALK Agreement; Out-Licenses. GBP hereby acknowledges that it has received copies
of the SALK Agreement and Out-Licenses and has reviewed and understood the terms and conditions
thereof. GBP agrees to be strictly bound by the terms and conditions of the SALK Agreement and the
Out-Licenses and to fully perform, or caused to be performed, its obligations and duties under the
terms and conditions of the same after the Effective Date.

6.7 Assistance with Prosecution of Patents. CGI shall reasonably cooperate with GBP
in connection with the preparation and filing of any applications for registration, maintenance,
and other documentation reasonably determined by GBP to be necessary or advisable to obtain,
protect, or preserve GBP’s rights in any Acquired IP or SALK IP Rights after the Effective Date.
Any actual and reasonable out-of-pocket expenses associated with such reasonable assistance shall
be borne by GBP.

6.8 Documentation. CGI agrees to provide to GBP copies of: (a) all files of the
pending patent applications constituting the Acquired IP and the names and addresses of counsel who
are currently involved in the prosecution thereof, and (b) copies of other relevant documents, if
any, in CGI’s possession that relate to the Acquired IP, including the prosecution histories of
Patents constituting Acquired IP.

6.9 Excluded Assets; No Implied Licenses. Notwithstanding anything herein to the
contrary, any billed or unbilled receivables owed to CGI under the Out-Licenses or the SALK
Agreement that have accrued or are due before the Effective Date are specifically excluded from the
assets transferred to GBP hereunder and such receivables shall be payable by the applicable party
to CGI. Nothing contained in this Agreement shall be construed as conferring (i) any ownership
rights to any Intellectual Property Rights, Technology or any other assets (whether tangible or
intangible) owned or controlled by CGI other than those expressly transferred under Article II of
this Agreement, or (ii) any license rights, by implication, estoppel or otherwise, under any
Intellectual Property Rights owned or controlled by CGI, other than as expressly transferred or
granted in Article II of this Agreement.

6.10 Technical Assistance. Except as provided under Section 2.2, neither Party shall
be required to provide the other Party with any technical assistance or to furnish the other Party
with, or obtain on their behalf, any documents, materials or other information or Technology.

ARTICLE VII

PAYMENTS

7.1 Payments. In exchange and as consideration for the Acquired IP and Provided
Technology and other Intellectual Property Rights licensed and/or offered to be licensed to GBP
hereunder, GBP shall pay CGI a one-time, non-refundable fee of Twelve Million US Dollars
($12,000,000) (“Fee”) upon the Effective Date.

7.2 Payment Terms. All payments paid under this Agreement shall be non-refundable.
The Fee shall be paid by GBP to CGI in US Dollars by electronic transfer of funds, as follows:

Name of Payee: Cell Genesys, Inc.

Address: 500 Forbes Blvd., South San Francisco, CA 94080

Bank:

ABA Number:

Bank Address:

Account Number:

7.3 Taxes. Each Party shall be responsible for its own taxes (including without
limitation any sales, use or value-added taxes), duties, tariffs or other similar charges
(“Taxes”) incurred in connection with each Party’s performance under this Agreement. If
GBP concludes, after consultation with CGI, that Tax withholdings are required under applicable law
with respect to any payments due CGI hereunder, GBP shall withhold the required amount and pay it
to the appropriate governmental authority. Any such Tax required to be withheld shall be an
expense of and borne solely by CGI. To the extent required by law, GBP shall pay Taxes deducted
and withheld from payments payable hereunder to the appropriate governmental authorities on behalf
of CGI.

ARTICLE VIII

CONFIDENTIAL INFORMATION

8.1 Confidentiality. Each Party acknowledges that it may obtain confidential,
non-public information under this Agreement (“Proprietary Information”) of the other Party.
The Party receiving the Proprietary Information (“Receiving Party”) of the other Party
(“Disclosing Party”) shall for ten (10) years after the initial disclosure of the
applicable Proprietary Information, keep in confidence and trust all of the Disclosing Party’s
Proprietary Information received by it. The Receiving Party shall not use the Proprietary
Information of the Disclosing Party other than as expressly permitted under the terms of this
Agreement or by a separate written agreement. The Receiving Party shall take all reasonable steps
to prevent unauthorized disclosure or use of the Disclosing Party’s Proprietary Information and to
prevent it from falling into the public domain or into the possession of unauthorized persons. The
Receiving Party shall not disclose Proprietary Information of the Disclosing Party to any person or
entity other than its officers, employees, consultants and permitted sublicensees, who need access
to such Proprietary Information in order to effect the intent of this Agreement and who have
entered into written confidentiality agreements which protect the Proprietary Information of the
Disclosing Party under no less protective terms as contained herein, or to its respective
attorneys, auditors or bankers who will abide to the confidentiality provisions herein. The
Receiving Party shall immediately give notice to the Disclosing Party of any unauthorized use or
disclosure of Disclosing Party’s Proprietary Information. Without in any way limiting the
Disclosing Party’s rights, in law or equity, against the Receiving Party or any Third Party, the
Receiving Party agrees to provide reasonable assistance to the Disclosing Party to remedy such
unauthorized use or disclosure of its Proprietary Information. For clarity, any non-public
information provided to GBP by CGI pursuant to Section 6.7 or Section 6.8, (“Non-Public Patent
Related Information”) shall be considered GBP’s Proprietary Information after the Effective
Date. For further clarity, Non-Public Patent Related Information shall not be considered CGI’s
Proprietary Information hereunder after the Effective Date.

8.2 Exceptions. The obligations under Section 8.1 above shall not apply to the extent
that the Proprietary Information is information which:

(a) is already known to the Receiving Party without an obligation of confidentiality at
the time of disclosure (including, with respect to CGI, Non-Public Patent Related
Information), which knowledge the Receiving Party shall have the burden of proving;

(b) is, or, through no act or failure to act of the Receiving Party, becomes publicly
known;

(c) is rightfully received by the Receiving Party from a Third Party without
restriction on disclosure;

(d) is independently developed by the Receiving Party after the Effective Date without
reference or access to the Proprietary Information of the Disclosing Party, which
independent development the Receiving Party will have the burden of proving; or

(e) is approved for release by written authorization of the Disclosing Party.

8.3 Disclosure to Government Agencies. Nothing in this Agreement shall prevent the
Receiving Party from disclosing Proprietary Information to the extent the Receiving Party is
legally compelled to do so by any governmental investigative or judicial agency pursuant to
proceedings over which such agency has jurisdiction; provided, however, that as soon as reasonably
possible and, in any event, prior to any such disclosure, the Receiving Party shall (a) assert the
confidential nature of the Proprietary Information to the agency; (b) if legally permissible,
immediately notify the Disclosing Party in writing of the agency’s order or request to disclose;
and (c) cooperate fully with the Disclosing Party in protecting against any such disclosure and/or
obtaining a protective order narrowing the scope of the compelled disclosure and protecting its
confidentiality. The Receiving Party may also disclose Proprietary Information of the Disclosing
Party to the extent required under any applicable disclosure requirements of the U.S. Securities
and Exchange Commission or any other securities exchange or market; provided, however, that the
Receiving Party shall provide prior notice of such intended disclosure to the Disclosing Party if
possible under the circumstances and shall disclose only such Proprietary Information of the
Disclosing Party as is reasonably required to be disclosed.

ARTICLE IX

INDEMNITY OBLIGATIONS; LIMITATION OF LIABILITY

9.1 Indemnification by GBP. GBP shall indemnify, defend, and hold harmless CGI and
its Affiliates and their respective directors, board members, officers, employees, agents and
independent contractors and their respective successors, heirs and assigns against any liability,
damage, loss, or expense (including reasonable attorneys’ fees and expenses) arising from a Third
Party claim arising out of any theory of liability (including actions in the form of tort,
warranty, or strict liability and regardless of whether such action has any factual basis)
concerning:

(a) any product, process, or service made, used, sold, imported, or performed by GBP or
its Affiliates, or sublicensees pursuant to any right or license transferred or granted to
GBP under this Agreement;

(b) GBP’s material breach of its representations or warranties made herein;

(c) any act or omission of GBP or its Affiliates or sublicensees occurring on or after
the Effective Date that is a material breach of the Out-Licenses or the SALK Agreement; and

(d) GBP’s material breach of the last paragraph of Section 2.1 or Section 6.6 of this
Agreement;

in each case (a), (b), (c) or (d), except to the extent that any such claim results from or as a
result of any misrepresentation, negligence or willful misconduct by CGI or its Affiliates.

9.2 Indemnification by CGI. CGI shall indemnify, defend, and hold harmless GBP and
its Affiliates and their respective directors, board members, officers, employees, agents and
independent contractors and their respective successors, heirs and assigns against any liability,
damage, loss, or expense (including reasonable attorneys’ fees and expenses) arising from a Third
Party claim arising out of any theory of liability (including actions in the form of tort,
warranty, or strict liability and regardless of whether such action has any factual basis)
concerning:

(a) any product, process, or service that is made, used, sold, imported, or performed
by CGI as a result of CGI’s exercise of its rights granted under Article IV of this
Agreement;

(b) CGI’s material breach of any of the representations or warranties made herein; or

(c) any existing conflicts, if any, between the Out-Licenses as of the Effective Date.

in each case (a), (b) or (c), except to the extent that any such claim results from or as a result
of any misrepresentation, acts, omissions, negligence or willful misconduct by GBP or its
Affiliates.

9.3 Procedures. In the event that any Party entitled to indemnification under Section
9.1 or 9.2 (an “Indemnitee”) is seeking such indemnification Indemnitee agrees to provide
the indemnifying Party with prompt written notice of any claim, suit, action, demand, or judgment
for which indemnification is sought under this Agreement. The indemnifying Party agrees, at its
own expense, to provide attorneys reasonably acceptable to Indemnitee to defend against any such
clam. The Indemnitee shall cooperate fully with the indemnifying Party in such defense and will
permit the indemnifying Party to conduct and control such defense and the disposition of such
claim, suit, or action (including all decisions relative to litigation, appeal, and settlement);
provided, however, that any Indemnitee shall have the right to retain its own
counsel if representation of such Indemnitee by the counsel retained by the indemnifying Party
would be inappropriate because of actual or potential differences in the interests of such
Indemnitee and any other party represented by such counsel. Such counsel retained by an Indemnitee
may participate in the defense and disposition of such claim; provided that the indemnifying Party
is allowed to conduct and control such defense and disposition. The indemnifying Party agrees to
keep the Indemnitee informed of the progress in the defense and disposition of such claim and to
consult with the Indemnitee with regard to any proposed settlement; provided that the indemnifying
Party shall not dispose of or settle any such claim in any manner which results in an admission of
liability or an agreement to make payments by Indemnitee, or otherwise adversely affects
Indemnitee’s rights or interests, without the Indemnitee’s prior written consent.

9.4 Limitation of Liability. EXCEPT FOR A BREACH OF Article VIII, OR WITH RESPECT TO
THE INDEMNIFICATION OBLIGATIONS UNDER Article IX, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST
PROFITS, HOWEVER CAUSED AND BASED ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY
WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

ARTICLE X

MISCELLANEOUS

10.1 Submission to Jurisdiction; Consent to Service of Process. Any litigation
against either Party hereto, including any to enforce any judgment entered by any court in respect
thereof, shall be brought in any federal or state court of competent jurisdiction located in New
York County in the State of New York, and the Parties hereto hereby irrevocably submit to the
exclusive jurisdiction of any federal or state court located within New York County in the State of
New York, over any such action. The Parties hereby irrevocably waive, to the fullest extent
permitted by applicable law, any objection which they may now or hereafter have to the laying of
venue of any such action brought in such court or any defense of inconvenient forum for the
maintenance of such action. Each of the Parties hereto agrees that a judgment in any such action
may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by
law.

10.2 Additional Actions and Documents. Each of the Parties hereby agrees use
commercially reasonable efforts to take or cause to be taken such further actions, to execute,
acknowledge, deliver and file or cause to be executed, acknowledged, delivered and filed such
further documents and instruments, and to use commercially reasonable efforts to obtain such
consents, as may be necessary or as may be reasonably requested to fully effectuate the purposes,
terms and conditions of this Agreement, whether at or after the Effective Date. For the avoidance
of doubt, CGI agrees to execute all documents necessary to assign to GBP any Patents owned by CGI
and included within CGI’s Patent portfolio as of the Effective Date related to lentiviral vector
technology for the compositions and methods for making lentiviral particles that were not but
should have been included in the Acquired IP as of the Effective Date, which such Patents shall be
considered Acquired IP subject to the terms and conditions of this Agreement.

10.3 Notices. All notices and other communications under this Agreement shall be in
writing and shall be deemed given (a) when delivered personally by hand (with written confirmation
of receipt); (b) when sent by facsimile (with written confirmation of transmission); or (c) one
business day following the day sent by overnight courier (with written confirmation of receipt), in
each case at the following addresses and facsimile numbers (or to such other address or facsimile
number as a Party may have specified by notice given to the other Party pursuant to this
provision):

If to CGI, to:

Cell Genesys, Inc.

500 Forbes Boulevard

South San Francisco, California 94080

Facsimile: (650) 266-2940

Attention: Senior Vice President, Corporate Department

With a copy (which shall not constitute notice) to:

O’Melveny & Myers

2765 Sand Hill Road

Menlo Park, California 94025

Facsimile: (650) 473-2601

Attention: Ms. Margaret Chu Ikeya

If to GBP, to:

GBP IP, LLC

537 Steamboat Road

Greenwich, CT 06830

Attn: David S. Wetherell

With a copy (which shall not constitute notice) to:

BRL Law Group LLC

31 St. James Avenue, Suite 850

Boston, MA 02116

Facsimile: (617) 399-6930

Attention: Thomas B. Rosedale

10.4 Entire Agreement; Amendments and Waivers. This Agreement (including all
appendices, exhibits, schedules and other attachments) represents the entire understanding and
agreement between the Parties hereto with respect to the subject matter hereof and supersedes all
prior negotiations and drafts of the Parties with regard to the transactions contemplated herein
and therein. This Agreement can be amended, supplemented or changed, and any provision hereof can
be waived, only by written instrument making specific reference to this Agreement signed by the
Party against whom enforcement of any such amendment, supplement, modification or waiver is sought.
No action or nonaction taken pursuant to this Agreement, including without limitation, any
investigation by or on behalf of any Party, shall be deemed to constitute a waiver by the Party
taking such action or nonaction of compliance with any representation, warranty, covenant or
agreement contained herein. The waiver by any Party hereto of a breach of any provision of this
Agreement shall not operate or be construed as a further or continuing waiver of such breach or as
a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and
no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of such right, power or remedy by such Party preclude any
other or further exercise thereof or the exercise of any other right, power or remedy.

10.5 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and performed in such state,
without giving effect to its principles of conflicts of law.

10.6 Binding Effect; Assignment. This Agreement shall be binding upon and inure to
the benefit of the Parties and their respective successors and permitted assigns. Nothing in this
Agreement shall create or be deemed to create any Third Party beneficiary rights in any Person not
a party to this Agreement. No assignment or transfer of this Agreement or of any rights or
obligations hereunder may be made by either Party, directly or indirectly (by operation of law or
otherwise), without the prior written consent of the other Party, and any attempted assignment
without the required consent shall be void; provided, however, that either Party
shall have the right to transfer or assign this Agreement to an entity that acquires all or
substantially all of business or assets of such Party to which this Agreement relates, whether by
merger, reorganization, acquisition, sale, or otherwise, and agrees to be strictly bound by the
terms and conditions of this Agreement.

10.7 Good Faith Performance. The Parties agree to cooperate fully to work in good
faith and mutually to assist each other in the performance of this Agreement. In this regard, the
Parties will meet and consult to seek to resolve any problems and disputes under this Agreement.

10.8 Severability. If any term or other provision of this Agreement is invalid,
illegal, or incapable of being enforced by any law or public policy, all other terms or provisions
of this Agreement shall nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any manner materially
adverse to any Party. Upon such determination that any term or other provision is invalid,
illegal, or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the Parties as closely as possible in an
acceptable manner in order that the transactions contemplated hereby are consummated as originally
contemplated to the greatest extent possible.

10.9 Counterparts; Language. This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this Agreement and all of
which, when taken together, will be deemed to constitute one and the same agreement. This
Agreement shall be drafted in English only.

10.10 No Agency. Nothing in this Agreement shall be construed as establishing a joint
venture or an agency relationship between the Parties. Neither Party shall have, or shall
represent that it has, any power, right or authority to bind the other Party to any obligation or
liability.

10.11 Rules of Construction. This Agreement shall be construed without regard to any
presumption or rule requiring construction or interpretation against the Party drafting or causing
any instrument to be drafted. The words “hereof, “herein” and “hereunder” and words of similar
import when used in this Agreement will refer to this Agreement as a whole (including any annexes,
exhibits and schedules to this Agreement) and not to any particular provision of this Agreement,
and section and subsection references are to this Agreement unless otherwise specified. The words
“include”, “including”, or “includes” when used herein shall be deemed in each case to be followed
by the words “without limitation” or words having similar import. The headings in this Agreement
are included for convenience of reference only and will not limit or otherwise affect the meaning
or interpretation of this Agreement. The meanings given to terms defined herein will be equally
applicable to both the singular and plural forms of such terms.

10.12 Force Majeure. Neither Party shall be liable hereunder by reason of any failure
or delay in the performance of its obligations hereunder on account of strikes, shortages, riots,
insurrection, fires, flood, storm, explosions, acts of God, war, governmental action, labor
conditions, earthquakes, material shortages or any other causes that are beyond the reasonable
control of such Party.

[SIGNATURE PAGES FOLLOW]

2

IN WITNESS WHEREOF, the Parties have caused this Technology and Intellectual Property
Agreement to be duly executed as of the Effective Date.

CELL GENESYS, INC.

By:

Name: Robert H. Tidwell

Title: Senior Vice President, Corporate Development

GBP IP, LLC

By:

Name:

Title:

3

Solely as a guarantor of GBP under the terms of Section 6.2 above, Greenwich Biotech
Management LLC, on behalf of itself and its Affiliates, acknowledges and assents to the terms of

this Agreement as of the date set forth above and hereby agrees to be bound by the terms of Section
6.2 of this Agreement.

Greenwich Biotech Management LLC

By:

Name:

Title:

[GREENWICH BIOTECH MANAGEMENT LLC SIGNATURE PAGE ACKNOWLEDGING AND ASSENTING TO THE TECHNOLOGY AND

INTELLECTUAL PROPERTY AGREEMENT]

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]